mammary gland type A adenocarcinoma ER+, PR+, HER2-(MCF-7), triple-negative breast cancer ER-, PR-, HER2- (MDA-MB-231) and breast, non-tumorigenic epithelial cell line, using the standard MTT-dye reduction assay in which the conjugates showed moderate antiproliferative activity. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.